A new study reveals that taking tirzepatide once a week can lead to significant and long-lasting weight loss for up to three ...

The study, led by Dr Luca Busetto from the University of Padova in Italy and colleagues from Eli Lilly and Company that ...

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that around ...

Taking tirzepatide drug once a week may produce clinically meaningful and sustained weight loss for at least 3 years in ad ...

Physicians are turning to other options, including older, cheaper medications, as compounding GLP-1s comes to an end.

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that around two thirds of participants of the SURMOUNT-1 trial had only regained 5% ...

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that patients ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

You may know about tirzepatide, also known as Mounjaro or Zepbound, due to its popularity for those looking to lose weight or treat diabetes. Now, researchers have gotten it approved to treat sleep ...

Karen Coe, 59, who has type 2 diabetes, says she was prescribed a GLP-1 medication to help her lose weight and get her ...

Eli Lilly just pre-announced a $1.57 billion pre-tax charge related to acquired in-process R&D, which is expected to weigh ...